Cargando…
Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398814/ https://www.ncbi.nlm.nih.gov/pubmed/30819682 http://dx.doi.org/10.1136/bcr-2018-227865 |
_version_ | 1783399646302830592 |
---|---|
author | Freitag, Julien Wickham, James Shah, Kiran Tenen, Abi |
author_facet | Freitag, Julien Wickham, James Shah, Kiran Tenen, Abi |
author_sort | Freitag, Julien |
collection | PubMed |
description | The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336). |
format | Online Article Text |
id | pubmed-6398814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-63988142019-03-21 Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis Freitag, Julien Wickham, James Shah, Kiran Tenen, Abi BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336). BMJ Publishing Group 2019-02-27 /pmc/articles/PMC6398814/ /pubmed/30819682 http://dx.doi.org/10.1136/bcr-2018-227865 Text en © BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Freitag, Julien Wickham, James Shah, Kiran Tenen, Abi Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title | Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title_full | Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title_fullStr | Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title_full_unstemmed | Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title_short | Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
title_sort | effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis |
topic | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398814/ https://www.ncbi.nlm.nih.gov/pubmed/30819682 http://dx.doi.org/10.1136/bcr-2018-227865 |
work_keys_str_mv | AT freitagjulien effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis AT wickhamjames effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis AT shahkiran effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis AT tenenabi effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis |